Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cousin

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
ESMO Open|December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomasD M Filippini, B Cabarrou, C Dupain, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2023
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trialJ Remon, B Besse, S Ponce Aix, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2022
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitorsF Peyraud, J-P Guégan, D Bodet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2018
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumorsA Italiano, J R Infante, G I Shapiro, et al.
ESMO Open|December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomasD M Filippini, B Cabarrou, C Dupain, et al.
Pageof 4